Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

∙ Participants are eligible to be included in the study only if all of the following criteria apply:

• Participant must have CIDP or possible CIDP criteria, based on European Academy of Neurology (EAN)/ Peripheral Nerve Society (PNS) Task Force CIDP guidelines, second revision (2021).

• Participant must have either typical CIDP, or one of the following two CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis Sumner Syndrome). Diagnosis must be confirmed by the adjudication committee.

• Participant must be refractory to either immunoglobulin therapy or corticosteroid therapy, as defined below.

‣ Immunoglobulin-refractory subgroup: Historic evidence of failure or inadequate response to immunoglobulin therapy prior to screening

⁃ Corticosteroid-refractory subgroup: Historic evidence of failure or inadequate response to corticosteroid therapy prior to screening

• Participant has an INCAT score of 2 to 9

• Any allowed immunosuppressant drugs (azathioprine, cyclosporine, or mycophenolate mofetil) have been taken for ≥6 months

• Participant may be receiving low-dose oral corticosteroids (≤20 mg/day of prednisone or equivalent)

• Participant must have active disease, defined by a CIDP disease activity score (CDAS) of ≥ 2 points at Screening

• Participant must have documented vaccinations against encapsulated bacterial pathogens given within 5 years prior to Day 1 or initiated a minimum of 14 days prior to first dose of study intervention

• Contraception for sexually active male or female participants; not pregnant or breastfeeding; no sperm donating for male participant

• A body weight at Screening of 35 kg to 154 kg (77 to 340 lbs), inclusive